Effects of Treatment with Megestrol Acetate, Aminoglutethimide, or Formestane on Insulin-Like Growth Factor (IGF) I and II, IGF-Binding Proteins (IGFBPs), and IGFBP-3 Protease Status in Patients with Advanced Breast Cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2216-2221

  Frost, Victoria J ^a   Helle, Svein I ^c   Lønning, Per E ^c   Van Der Stappen, Jos W J ^b   Holly, Jeff M P ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; CORTISONE ACETATE; FORMESTANE; MEGESTROL ACETATE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANDROSTENEDIONE; AROMATASE INHIBITORS; BLOTTING, WESTERN; BREAST NEOPLASMS; ENDOPEPTIDASES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MEGESTROL ACETATE; MIDDLE AGED; RADIOIMMUNOASSAY; SOMATOMEDINS;

EID: 0029938078     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.81.6.8964854     Document Type: Article

References (39)

1. Santen RJ, Manni A, Harvey H, Redmond C. 1990 Endocrine treatment of breast cancer in women. Endocr Rev. 11:221-265.
2. Loønning PE, Lien EA, Lundgren S, Kvinnsland S. 1992 Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet. 22:327-358.
3. Horwitz KB. 1993 Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat. 26:119-130.
4. Smith IE, Harris AL, Morgan M, Gazet J-C, McKinna JA. 1992 Tamoxifen versus aminoglutethimide versus combined lamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 42(Suppl):3430-3433.
5. Kvinnsland S, Lønning PE, Dahl O. 1984 Treatment of breast carcinoma with aminoglutethimide. Acta Radiol Oncol. 23:421-424.
6. Colletti RB, Roberts DJ, Devlin JT, Copeland KC. 1989 Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 49:1881-1884.
7. Pollak MN, Constantino J, Polychronakos C, Blauer S, Guyda H, Margolese M. 1990 Insulin-like growth factor levels in stage I breast cancer patients. J Natl Cancer Inst. 82:1693-1697.
8. Lien EA, Johannessen DC, Aakvaag A, Lonning PE. 1992 Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I in breast cancer patients. J Steroid Biochem Molec Biol. 41:541-543.
9. Karey KP, Sirbasku DA. 1988 Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res. 48:4083-4092.
10. Jammes H, Peyrat J-P, Ban E, et al. 1992 Insulin-like growth factor I receptors in human breast tumour: localization and quantification by histo- autoradiographic analysis. Br J Cancer. 66:248-253.
11. Cohick WS, Clemmons DR. 1993 The insulin-like growth factors. Annu Rev Physiol. 55:131-153.
12. Lonning PE, Hall K, Aakvaag A, Lien EA. 1992 Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein 1 in breast cancer patients. Cancer Res. 52:4719-4723.
13. Giudice LC, Farrel EM, Pham H, Lamson G, Rosenfeld R. 1990 Insulin- like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab. 71:806-816.
14. Hossenlopp P, Segovia B, Lasarre C, Roghani M, Bredon M, Binoux M. 1990 Evidence of enzymatic degradation of insulin-like growth factor binding proteins in the 150 K complex during pregnancy. J Clin Endocrinol Metab. 71:797-805.
15. Frost VJ, Macaulay M, Wass JAH, Holly JMP. 1993 Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. J Endocrinol. 138:545-554.
16. Holly JMP, Biddlecombe RA, Dunger DB, et al. 1988 Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: a new role for insulin? Clin Endocrinol (Oxf). 29:667-675.
17. Davies SC, Wass JAH, Ross RJM, et al. 1991 The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol. 130:469-473.
18. Cwyfan Hughes SC, Wass JAH, Holly JMF. 1993 Two site-specific radioimmunoassays which demonstrate the presence of proteolytically modified insulin-like growth factor-binding protein-3 in the circulation. J Endocrinol. 137:321-328.
19. Coulson VJ, Wass JAH, Abdulla AF, Cotterill AM, Holly JMP. 1991 Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul. 1:119-124.
20. Hossenlopp P, Seurin D, Segovia-Quinson B, Lassarre C, Hardouin S, Binoux M. 1986 Analysis of serum insulin-like growth factor binding proteins using Western ligand blotting: use of the method of titration of the binding proteins and competitive binding studies. Anal Biochem. 154:138-143.
21. Lamson G, Giudice LC, Rosenfeld RG. 1991 A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab. 72:1391-1393.
22. Lønning PE, Helle S-I, Johannessen DC, et al. 1995 Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol (Oxf). 42:23-30.
23. Weissberger AJ, Ho KKY, Lazarus L. 1991 Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmeno-pausal women. J Clin Endocrinol Metab. 72:374-381.
24. Slowinska-Srzednicka J, Zgliczynski S, Jeske W, et al. 1992 Transdermal 17β-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest. 15:533-538.
25. Dawson-Hughes B, Stern D, Goldman J, Reichlin S. 1986 Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiologic estrogen replacement. J Clin Endocrinol Metab. 63:424-432.
26. Duursma SA, Bijlsma JWL, van Paassen HC, van Buul-Offers SC, Skottner-Lundin A. 1984 Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in postmenopasal women; a pilot study. Acta Endocrinol (Copenh). 106:527-531.
27. Reed M, Christodoulides R, Koistinen R, Seppala M, Teale JD, Ghilchik MW. 1992 The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-I in women with advanced breast cancer. Int J Cancer. 52:208-212.
28. Ferrari L, Zilembo N, Bajetta E, et al. 1994 Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer. Breast Cancer Res Treat. 30:127-132.
29. Baxter RC. 1988 Characterization of the acid-labile subunit of the growth hormone dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 67:265-272.
30. Holly JMP, Claffey DCP, Cwyfan-Hughes SC, Frost V, Yateman ME. 1993 Proteases acting on IGFBPs: their occurrence and physiological significance. Growth Regul. 3:88-91.
31. Lassarre C, Binoux M. 1994 Insulin-like growth factor binding protein-3 is functionally altered in pregnancy serum. J Clin Endocrinol Metab. 134:1254-1262.
32. Davies SC, Wass JAH, Ross RJM, et al. 1991 The induction of a specific protease for insulin-like growth factor-binding protein 3 during severe illness. J Endocrinol. 130:469-473.
33. Müller HL, Gargosky SE, Lehrnbecher T, Hintz RL, Rosenfeld RG. 1993 Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebro-spinal fluid of children with leukemia, central nervous tumor, or meningitis. J Clin Endocrinol Metab. 77:1113-1119.
34. Cwyfan Hughes SC, Cotterill AM, Molloy AR, et al. 1992 The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol. 135:135-145.
35. Lønning PE, Kvinnsland S. 1988 Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 35:685-710.
36. Miell JP, Corder R, Pralong FP, Gaillard RC. 1991 Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentra-tions in normal male volunteers. J Clin Endocrinol Metab. 72:675-681.
37. Gourmelen M, Girard F, Binoux M. 1982 Serum somatomedin/insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushings syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab. 54:885-892.
38. Lønning PE, Scanche JS, Kvinnsland S, Ueland PM. 1985 Single-dose and steady state pharmacokinetics of aminoglutethimide. Clin Pharmacokinet. 10:353-364.
39. Manni A, Badger B, Wei L, et al. 1994 Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res. 54:2934-2942.